Joe Chang

Radiation Oncologist. Views are my own.

[ASTRO @ASTRO_org]

The latest edition of the #RedJournal is a special issue featuring the results of the High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC) project. The HyTEC special issue of the Red Journal is available now online at https://t.co/NO1G4oMlye #RadOnc

[arjun sahgal @SahgalArjun]

Published in late breaking abstracts last night

[Joost Verhoeff @joostverhoeff]

SH 01 - Science Highlights - (CNS) Central Nervous System.

@JingLi_MD_PhD from @MDAndersonNews presents the results of phase 3 WBRT vs SRS for patients with 4-15 brain mets.

Same OS ✅
Less cognitive impairment ✅

🙏 please cease with WBRT

#astro20 #radonc #btsm

[Jonathan Tomaszewski @dr_jonathant]

LungART abstract online @myESMO:

Stage III-N2 NSCLC (R0) randomised to +/- mediast PORT:
❌ no ss DFS benefit
⬆️ severe acute/late cardiopulm tox

⚠️higher than anticipated DFS both arms
⚠️await additional endpoints & subgroups (presentation pending)
#radonc #lcsm #ESMO20

[Melvin LK CHUA | FRCR, PhD, FASCO @DrMLChua]

Very pleased to share the results of our RCT on consolidation RT in metastatic NPC changing the paradigm of how we think of treating metastatic disease and altering disease trajectory! #nasopharyngealcarcinoma #radiotherapy #metastasis @JAMAOnc

[Tim Kruser @TimothyKruserMD]

reRT for GBM--worthwhile?
RTOG 1205 (-) at SNO 2019.
3 potential reasons:
A) not enough dose
B) fields too small or
C) just a futile approach

A small RCT looks at higher dose (8 Gy x 4 on Bev) and is a bit more promising...

What do you do, & why? #btsm

https://t.co/e8bcbsQ5FI

[Stephen Ramey @StephenRameyMD]

Wow. 83% of patients with G3 co-deleted gliomas progressed with temozolomide alone vs. 37% in RT arms (RT alone or RT + TMZ).

Small pt numbers but emphasizes importance of RT. ☢️#radonc

Will be interesting to see RT + PCV vs. RT + TMZ results.

[Joe Chang @joehchang]

ROSEL, STARS, ACOSOG-RTOG, and now SABRTooth have failed to accrue for surgery vs SABR RCTs. Lessons to be learnt for still accruing STABLE-MATES, POSTILV, and VALOR? #radonc

[@RadOncPapers @radoncpapers]

SABRTOOTH: A randomised controlled feasibility study of Stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of… https://t.co/EyECvIQKEb h/t @NCBI #RadOnc #PubMed

[Joe Chang @joehchang]

@jryckman3 @CJTsaiMDPhD @drlorenmell @BarbaraBurtness @imrtlee @KimpleRandall @subatomicdoc True this is probably T3 which is more straightforward. More controversy and discussion points with the T1-2N1 group though😃

[Joe Chang @joehchang]

@CJTsaiMDPhD @drlorenmell @BarbaraBurtness @imrtlee @KimpleRandall @subatomicdoc Good point re: MACH-NC. Most guidelines still say RT alone preferred in AJCC v7 T1-2N1 though. Do you think guidelines need updating (at least to reflect equipoise between RT and CCRT if not CCRT preferred outright)?

[C. Jillian Tsai, MD, PhD @CJTsaiMDPhD]

To Intensify or Not to Intensify? Red J Gray Zone discussions regarding management of p16+ oropharyngeal cancer. #hnsm @drlorenmell @BarbaraBurtness @imrtlee @KimpleRandall @subatomicdoc
https://t.co/GU3J4Vy4Pu

[Joe Chang @joehchang]

@CJTsaiMDPhD @drlorenmell @BarbaraBurtness @imrtlee @KimpleRandall @subatomicdoc Isn’t our “textbook” answer that those with T1-2 N1 disease be treated with RT alone (prob accel frac) according to @NCCN and @ASTRO_org guidelines because pts with this stage are underrepresented in chemoRT trials? #gyzone 2/4

[Joe Chang @joehchang]

@CJTsaiMDPhD @drlorenmell @BarbaraBurtness @imrtlee @KimpleRandall @subatomicdoc Good case. While I agree the pt would prob benefit from conc chemoRT, I’m less than “absolutely” certain that this is the right answer. #gyzone 1/4

[Angel Montero Luis @Monthy_A]

Preliminary Data Suggests Low-Dose Radiation May Be Successful Treatment For Severe Covid-19
#radonc #COVID19 https://t.co/6WlpgR2nG5

[Hien Le @twentyin5]

So happy and excited to see sod being turned at the Australian Bragg Centre site. Today’s press conference heralds the start of something significant for Australians #sahmri #protontherapy #australianbraggcentre

[JAMA Oncology @JAMAOnc]

An international multicenter analysis, FIRE-SCLC, reports encouraging outcomes with first-line stereotactic radiosurgery (SRS) for brain metastases from small-cell #lungcancer, with no decline in overall survival compared to whole-brain radiation (WBRT) https://t.co/hyOLy2jrCZ